WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to ...